The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years

Hely, Mariese A.; Morris, John G. L.; Traficante, Robert; Reid, Wayne G. J.; O'Sullivan, Dudley J.; Williamson, Peter M.
September 1999
Journal of Neurology, Neurosurgery & Psychiatry;Sep1999, p300
Academic Journal
No abstract available.


Related Articles

  • Parkinson Disease: A Review. Boe, Gerard P. // AMT Events;Jun2005, Vol. 22 Issue 2, p72 

    Presents information on Parkinson disease. Signs and symptoms; Progression of the disease; Findings of a study conducted by the National Parkinson Foundation on patients with Parkinsonism.

  • Levodopa and the Progression of Parkinson's Disease. Walton-Hadlock, Janice L. // New England Journal of Medicine;3/31/2005, Vol. 352 Issue 13, p1386 

    A letter to the editor is presented in response to a study on levodopa and the progression of Parkinson's Disease by the Parkinson Study Group in the December 9, 2004 issue.

  • Progression marker of Parkinson's disease: a 4-year multi-site imaging study. Burciu, Roxana G.; Ofori, Edward; Archer, Derek B.; Wu, Samuel S.; Pasternak, Ofer; McFarland, Nikolaus R.; Okun, Michael S.; Vaillancourt, David E. // Brain: A Journal of Neurology;Aug2017, Vol. 140 Issue 8, p2183 

    Progression markers of Parkinson's disease are crucial for successful therapeutic development. Recently, a diffusion magnetic resonance imaging analysis technique using a bitensor model was introduced allowing the estimation of the fractional volume of free water within a voxel, which is...

  • Genetic influence on the development of Parkinson’s disease. Riess, O.; Kuhn, W.; Krüger, R. // Journal of Neurology;Apr2000 Supplement 2, Vol. 247, pII69 

    In the last few years, the genetic contribution to Parkinson’s disease has gained major attention and resulted in the identification of four gene loci in autosomal dominant and autosomal recessive Parkinson’s disease. Several mutations in two genes have been shown to be responsible...

  • Deprenyl slows disease progression in early Parkinson's disease.  // Geriatrics;Nov1989, Vol. 44 Issue 11, p25 

    The article cites a study, which reports that deprenyl slows disease progression in early Parkinson's disease. According to California based researchers, early treatment of mild Parkinson's disease with deprenyl may slow disease progression. The researchers in this study followed 44 patients who...

  • Parkinson’s Disease and Cognitive Impairment. Yang, Yang; Tang, Bei-sha; Guo, Ji-feng // Parkinson's Disease (20420080);12/12/2016, p1 

    Parkinson’s disease (PD) is a progressive neurodegenerative disease primarily characterized by the hallmarks of motor symptoms, such as tremor, bradykinesia, rigidity, and postural instability. However, through clinical investigations in patients and experimental findings in animal models...

  • Perspectiva histórica y aspectos epidemiológicos de la enfermedad de Parkinson. García, Silvia; Suárez, Sergio Sauri; Dávalo, Erika Meza; Castillo, Juan Lucino // Medicina Interna de Mexico;ene/feb2008, Vol. 24 Issue 1, p28 

    Parkinson's disease is a neurodegenerative and progressive disease that at this moment has no curative treatment. We reviewed, from January 1970 to July 2007, these items: "Parkinson's disease", "PD", "parkinsonism", "epidemiology", "cohort study", "prevalence", "incidence", "risk factors",...

  • PARKINSON'S DRUG HELPS MORE IF GIVEN EARLIER.  // RN;Mar2009, Vol. 72 Issue 3, p20 

    The article discusses a follow-up study, published in "Movement Disorders," on the use of rasagiline (Azilect) for Parkinson's disease. It revealed that patients taking Azilect had a decreased risk of disease progression. Patients were followed for over six years and were allowed to take other...

  • Experimental drug may control Parkinson's disease.  // New York Amsterdam News;03/04/99, Vol. 90 Issue 10, p15 

    Details the study on a drug for Lou Gehrig's disease/ALS as a possible treatment to slow or stop the progression of Parkinson's disease. Description of the disease; Effect of the disease to Parkinson's patients.

  • Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up. Hariz, M. I.; Krack53, P.; Alesch, F.; Augustinsson, L.-E.; Bosch, A.; Ekberg, R.; Johansson, F.; Johnels, B.; Meyerson, B. A.; N'guyen, J.-P.; Pinter, M.; Pollak, P.; von Raison, F.; Rehncrona, S.; Speelman, J. D.; Sydow, O.; Benabid, A.-L. // Journal of Neurology, Neurosurgery & Psychiatry;Jun2008, Vol. 79 Issue 6, p694 

    Aim: To evaluate the results of ventral intermediate (Vim) thalamic deep brain stimulation )DBS) in patients with tremor predominant Parkinson's disease (PD) at 6 years post surgery. Methods: This was a prolonged follow-up study of 38 patients from eight centres who participated in a multicentre...


Read the Article


Sign out of this library

Other Topics